Acer Therapeutics expands development of ACER-801 into post-traumatic stress disorder. | Techy Kings


  • Acer Therapeutics Inc (NASDAQ: ACER) has expanded ACER-801 (osanetant) into a new indication for reducing the frequency and severity of acute stress disorder and post-traumatic stress disorder (PTSD).

  • The company says up to 20 percent of people who have experienced a traumatic event will develop PTSD in a single year, with more than 12 million adults with PTSD in the US.

  • Research at Emory University has analyzed thousands of genes that are activated in the brains of mice following fear conditioning events.

  • Tac2 is the upstream gene responsible for the production of the peptide Neurokinin B (NKB) in mice. The researchers showed that the Tac2 gene, which is specifically expressed by neurons in the amygdala, is required for processing fear memories. NKB and the specific receptor NK3R are also involved in the consolidation of fear memories.

  • By administering a potent and specific NK3R antagonist, osanetant, shortly after exposure to a traumatic event, they can strengthen fear memory.

  • Acer has granted exclusive worldwide rights to certain patents and patent applications from Emory University for the treatment or prevention of PTSD with osanetant.

  • Price Action: Shares of ACER were down 2.07% at $1.42 last check on Wednesday.

See more from Benzinga

Never miss real-time alerts on your stocks – join Benzinga Pro for free! Try a tool that helps you invest smarter, faster and better.

© 2022 Benzinga does not provide investment advice. all rights reserved.


Source link